CHD

Analyst Note: Church & Dwight Co., Inc. (CHD)

Date: 2026-06-13 Current Price: $95.63

1. Structural Readiness

State: Avoid

• Conservative Entry: Not yet defined (awaiting confirmed breakout).
• Aggressive/Pre-Breakout Entry: Not actionable on setup alone; price is currently holding above the structural support level.
• Breakout Level: Not yet triggered.
• Current Price: $95.63.
• Extension: Not applicable (price has not yet broken out to generate an extension metric).
• ATR Context: Current ATR is 2.4% (sub-threshold). This indicates low volatility relative to the historical "sweet spot" (4–6%). While this suggests a stable, low-volatility environment typical of defensive operators, it also implies a lack of immediate momentum or "fuel" for a rapid breakout.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None named at this date.

This is not a name driven by a specific macro secular thesis (e.g., "inflation hedge" or "demographic shift") in the current setup. The investment case is strictly tactical, relying on the quality of the technical setup (the forming coil) combined with the underlying business fundamentals. We must judge this name on the strength of its operational execution and the structural readiness of the price action, rather than inventing a macro narrative. The absence of a named thesis means conviction must be derived entirely from the evidence of business health and the probability of the technical breakout succeeding.

3. Business Overview

Company: Church & Dwight Co., Inc. (CHD) Industry: Consumer Staples (Household & Personal Care) Business Model: CHD develops, manufactures, and markets a broad portfolio of consumer household and personal care products, alongside specialty products for animal nutrition and industrial chemicals. The company operates through three principal divisions: Consumer Domestic, Consumer International, and Specialty Products.

Key Business Drivers & Evidence (as of 2026-06-13):

• Brand Portfolio: The company relies on seven "power brands" (ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, HERO, TOUCHLAND) which represent approximately 70% of net sales and profits.
• *Evidence:* [E9], [E13]
• Recent M&A Activity:
• Acquisition: Completed the acquisition of Touchland Holding Corp (developer of TOUCHLAND hand sanitizers) on July 16, 2025, for $656.0 million (net of cash), with a potential additional $159.0 million contingent payment based on 2025 sales thresholds.
• *Evidence:* [E14]
• Divestiture: Completed the sale of the VitaFusion and L'il Critters brands to Piping Rock Health Products, Inc. on December 31, 2025, streamlining the portfolio.
• *Evidence:* [E15]
• Growth & Innovation: Management expects new product launches to account for half of organic growth in 2026. Growth in the quarter was led by TheraBreath, ARM & HAMMER, Hero, and OxiClean, supported by strong innovation and distribution gains.
• *Evidence:* [E4], [E7]
• Financial Guidance (Management Expectations):
• Organic Growth: On track to deliver full-year organic growth of approximately 3% to 4%.
• *Evidence:* [E1]
• Margins: Expecting full-year gross margin expansion of approximately 100 basis points versus 2025.
• *Evidence:* [E2]
• EPS: Adjusted EPS expectation for 2026 remains at 5% to 8% growth.
• *Evidence:* [E3]
• Customer Concentration: Walmart remains the largest customer, accounting for approximately 23% of consolidated net sales.
• *Evidence:* [E17]
• Cost Structure: Intangible amortization expense is estimated at approximately $135.0 million in 2026, declining to $120.0 million annually over the next five years.
• *Evidence:* [E11]

4. Archetype and Conviction

Archetype: Defensive Operator Fit: The name fits the "Defensive Operator" archetype due to its focus on essential household goods, stable cash flows, and a business model designed to withstand economic cycles. The recent divestiture of VitaFusion/L'il Critters and acquisition of Touchland suggests a strategic shift toward higher-margin or more resilient categories (e.g., hand hygiene, laundry).

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The company has provided clear, specific guidance on growth (3-4% organic), margins (+100 bps), and EPS (5-8%), supported by recent M&A activity and brand performance data.
• Structural Quality: Moderate. The "Forming" coil indicates a stable base, but the lack of a confirmed breakout means the structural momentum is not yet proven.
• Setup Readiness: Partial. The setup is "Forming," which is a positive signal but not an entry signal. The stock is waiting for a catalyst to break the structure.
• Rerating Potential: Moderate. The combination of margin expansion guidance and a streamlined portfolio (post-divestiture) could support a multiple expansion if the breakout occurs.
• Valuation Context: Forward consensus EPS for FY1 is $3.75 and FY2 is $4.03. At a current price of $95.63, the stock trades at approximately 25.5x FY1 EPS. This is a premium valuation typical of high-quality defensive operators, requiring the execution of the 5-8% EPS growth and margin expansion to justify.

ATR Analysis: The current ATR of 2.4% is sub-threshold (below the 4% historical sweet spot). This confirms the "Defensive Operator" nature (low volatility) but suggests the stock lacks the immediate volatility required for a high-conviction momentum setup. A breakout from this low-volatility state would likely require a significant fundamental catalyst or a shift in market sentiment to generate the necessary volume and price expansion.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Margin Execution: Confirmation that the 100 bps gross margin expansion is being realized ahead of schedule.
• Innovation Success: Data showing new product launches are exceeding the "half of organic growth" target.

What Would Invalidate the Case:

• Guidance Miss: Any indication that the 3-4% organic growth or 5-8% EPS growth targets are at risk of being missed.
• Customer Concentration Risk: A significant loss of Walmart business or a sharp reduction in Walmart's order volume.

Gaps in Evidence:

• International Performance: While international sales are noted as 18% of consolidated sales, specific growth rates or headwinds in the International segment (Europe, Canada, Australia, Mexico) are not detailed in the provided evidence.
• Specialty Products Margin: The profitability and growth trajectory of the Specialty Products Division (animal nutrition/chemicals) are not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management guidance for 3-4% organic growth and 5-8% EPS growth; successful completion of Touchland acquisition and VitaFusion divestiture; structural "Forming" coil with price holding above support. Key risks: Sub-threshold ATR (2.4%) indicating low momentum; lack of confirmed breakout; high customer concentration with Walmart (23% of sales); premium valuation relative to growth rate. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs; current setup is not actionable for new capital. Expected path: Management continues to execute on margin expansion and innovation; price consolidates in the forming range until a catalyst triggers a breakout above resistance. Expected horizon: 3 to 6 months for a potential breakout or structural invalidation.